Abstract

In the update of selegiline (27 November 1989, page 95) we concluded that the drug had not been proven to delay the progression of Parkinson’s disease. Interim results from the large DATATOP trial now provides strong evidence that selegiline 10mg/day delays the untreated disease (The Parkinson Study Group. N Engl J. Med 1989; 321: 1364–71). The report appeared after we had gone to press.